6,309 Shares in Edwards Lifesciences Corporation $EW Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,309 shares of the medical research company’s stock, valued at approximately $571,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at about $266,000. NewEdge Advisors LLC grew its stake in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on EW. Evercore reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Piper Sandler restated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

EW opened at $89.89 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company’s 50 day simple moving average is $89.21 and its 200-day simple moving average is $84.67. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.